Pharma companies assess their ongoing reporting capabilities
The midnight oil is burning at many pharma companies as they make their final preparations for submitting aggregate-spending data to CMS by March 31, a requirement under the Physicians Sunshine Act. Recent reporting indicates that the Sunshine Act has already had an impact on physicians’ acceptance of speaker fees; now, Cegedim Relationship Management (Bedminster, NJ) is reporting that 64% of surveyed physicians say that the law will have an effect on their interactions with manufacturers, ranging from “not very much” to “greatly affect.” Only 14% of physicians indicated that “It won’t affect my interactions at all.”
Cegedim survey data indicate that the reporting tasks are setting up more or less as expected, with pharma companies more easily able to report spending sourced from its sales/marketing activities, and more difficultly for spending sourced from sponsored research. Forty-one percent of manufacturer-respondents are using a third-party IT system to compile their spending data; and 24% are currently using manual or spreadsheet-based processes. Just over half (51%) are using the same system for reporting sample distribution as for spend reporting (depending on the jurisdiction, both of these need to be reported in some cases). Overall, 76% of respondents prefer to have their aggregate-spend solution to include a “pre-integrated customer data solution,” i.e., a master customer dataset, which eases pairing up expenses with the specific healthcare provider. And they say that for planned future reporting methods, 53% say that they will eventually use a third-party system; 33% an internal system; and 14% a manual/spreadsheet process. By a 58-40% margin, respondents say that they expect investment in agg-spend reporting to increase in coming years.
Besides conducting the survey, Cegedim Relationship Management is an active player in they aggregate-spend reporting business, providing both a software platform, AggSpend360, and a master-data service, OneKey, for both national and global healthcare-provider identification. The full report is available, after registration, from Cegedim's site here.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.